Anika Therapeutics (ANIK) Tops Q1 EPS by 27c ; Offers Guidance
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $14.76 +1.17%
Revenue Growth %: +3.5%
Financial Fact:
Net income: 0.59
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +3.5%
Financial Fact:
Net income: 0.59
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.09, $0.27 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $40.5 million versus the consensus estimate of $41.55 million.
GUIDANCE:
Anika Therapeutics sees FY2024 revenue of $168-173 million, versus the consensus of $170.3 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras CEO says investors misunderstood margin guidance
- TD Cowen cuts Flowserve to Hold, flags guidance reset risk amid Mideast woes
- BMO Capital on FedEx (FDX): 'Guidance Appears Consistent With Our Forecasts'
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
